Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
When the US biotech company Regeneron Pharmaceuticals recently announced its first-quarter results, few were surprised that the company’s flagship wet age-related macular degeneration (AMD) product Eylea had once again exceeded consensus expectations. With three-monthly sales of $314 million, management reiterated that full-year revenues for 2013 are expected to hit $1.3 billion.
Hey, check out all the research scientist jobs. Post your resume today!
